MAPK3 and lung cancer: Of the four cell lines, only at 72 h of MCF7 breast and H1650 lung cancer showed elevated Akt levels upon methyl-donor treatment, which, however, was not associated with elevated proliferation at the latter probably due to the compensation by the reduced p-Erk1/2 levels.